References:
1. Jean, S.S., Lee, P.I., and Hsueh, P.R., Treatment options for COVID-19: The reality and challenges. J Microbiol Immunol Infect, 2020.53 (3): p. 436-443.
2. Beigel, J.H., Tomashek, K.M., Dodd, L.E., Mehta, A.K., Zingman, B.S., Kalil, A.C., Hohmann, E., Chu, H.Y., Luetkemeyer, A., Kline, S., Lopez de Castilla, D., Finberg, R.W., Dierberg, K., Tapson, V., Hsieh, L., Patterson, T.F., Paredes, R., Sweeney, D.A., Short, W.R., Touloumi, G., Lye, D.C., Ohmagari, N., Oh, M.D., Ruiz-Palacios, G.M., Benfield, T., Fatkenheuer, G., Kortepeter, M.G., Atmar, R.L., Creech, C.B., Lundgren, J., Babiker, A.G., Pett, S., Neaton, J.D., Burgess, T.H., Bonnett, T., Green, M., Makowski, M., Osinusi, A., Nayak, S., Lane, H.C., and Members, A.-S.G., Remdesivir for the Treatment of Covid-19 - Preliminary Report. N Engl J Med, 2020.
3. Group, R.C., Horby, P., Lim, W.S., Emberson, J.R., Mafham, M., Bell, J.L., Linsell, L., Staplin, N., Brightling, C., Ustianowski, A., Elmahi, E., Prudon, B., Green, C., Felton, T., Chadwick, D., Rege, K., Fegan, C., Chappell, L.C., Faust, S.N., Jaki, T., Jeffery, K., Montgomery, A., Rowan, K., Juszczak, E., Baillie, J.K., Haynes, R., and Landray, M.J.,Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med, 2020.
4. Li, G. and De Clercq, E., Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov, 2020.19 (3): p. 149-150.
5. Weiss, P. and Murdoch, D.R., Clinical course and mortality risk of severe COVID-19. Lancet, 2020. 395 (10229): p. 1014-1015.
6. Tale, S., Ghosh, S., Meitei, S.P., Kolli, M., Garbhapu, A.K., and Pudi, S., Post COVID -19 Pneumonia Pulmonary Fibrosis. QJM, 2020.
7. Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., Xiao, Y., Gao, H., Guo, L., Xie, J., Wang, G., Jiang, R., Gao, Z., Jin, Q., Wang, J., and Cao, B.,Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020. 395 (10223): p. 497-506.
8. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) . 2020 [cited 2020 29 september]; Available from: https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf.
9. Mehta, P., McAuley, D.F., Brown, M., Sanchez, E., Tattersall, R.S., Manson, J.J., and Hlh Across Speciality Collaboration, U.K.,COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet, 2020. 395 (10229): p. 1033-1034.
10. Piechotta, V., Chai, K.L., Valk, S.J., Doree, C., Monsef, I., Wood, E.M., Lamikanra, A., Kimber, C., McQuilten, Z., So-Osman, C., Estcourt, L.J., and Skoetz, N., Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.Cochrane Database Syst Rev, 2020. 7 : p. CD013600.
11. Tang, W., Cao, Z., Han, M., Wang, Z., Chen, J., Sun, W., Wu, Y., Xiao, W., Liu, S., Chen, E., Chen, W., Wang, X., Yang, J., Lin, J., Zhao, Q., Yan, Y., Xie, Z., Li, D., Yang, Y., Liu, L., Qu, J., Ning, G., Shi, G., and Xie, Q., Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ, 2020. 369 : p. m1849.
12. Lamontagne, F., Agoritsas, T., Macdonald, H., Leo, Y.S., Diaz, J., Agarwal, A., Appiah, J.A., Arabi, Y., Blumberg, L., Calfee, C.S., Cao, B., Cecconi, M., Cooke, G., Dunning, J., Geduld, H., Gee, P., Manai, H., Hui, D.S., Kanda, S., Kawano-Dourado, L., Kim, Y.J., Kissoon, N., Kwizera, A., Laake, J.H., Machado, F.R., Qadir, N., Sarin, R., Shen, Y., Zeng, L., Brignardello-Petersen, R., Lytvyn, L., Siemieniuk, R., Zeraatkar, D., Bartoszko, J., Ge, L., Maguire, B., Rochwerg, B., Guyatt, G., and Vandvik, P.O., A living WHO guideline on drugs for covid-19. BMJ, 2020. 370 : p. m3379.
13. Mo, X., Jian, W., Su, Z., Chen, M., Peng, H., Peng, P., Lei, C., Chen, R., Zhong, N., and Li, S., Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. Eur Respir J, 2020.55 (6).
14. Wilson, M.S. and Wynn, T.A., Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol, 2009. 2 (2): p. 103-21.
15. Kendall, R.T. and Feghali-Bostwick, C.A., Fibroblasts in fibrosis: novel roles and mediators. Front Pharmacol, 2014. 5 : p. 123.
16. Razzaque, M.S. and Taguchi, T., Pulmonary fibrosis: cellular and molecular events. Pathol Int, 2003. 53 (3): p. 133-45.